CHIKV Antigen (DAGC421)

Nature
Native
Tag/Conjugate
Unconjugated
Alternative Names
CHIKV; Chikungunya Virus
Procedure
None
Format
Liquid
Size
1 mL
Storage
Store at 2-8°C.
Introduction
CHIKV is formulated with purified, intact virus particles that have been chemically modified to render them non-infectious and refrigerator stable. Each vial contains 1.0 mL of CHIKV. CHIKV is supplied in a purified protein matrix that mimics the composition of a true clinical specimen.
Keywords
CHIKV; Chikungunya Virus

Citations


Have you cited DAGC421 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus

VIRUSES-BASEL

Authors: Lopez-Camacho, Cesar; Kim, Young Chan; Blight, Joshua; Moreli, Marcos Lazaro; Montoya-Diaz, Eduardo; Huiskonen, Juha T.; Kuemmerer, Beate Mareike; Reyes-Sandoval, Arturo

Chikungunya virus (CHIKV) has caused extensive outbreaks in several countries within the Americas, Asia, Oceanic/Pacific Islands, and Europe. In humans, CHIKV infections cause a debilitating disease with acute febrile illness and long-term polyarthralgia. Acute and chronic symptoms impose a major economic burden to health systems and contribute to poverty in affected countries. An efficacious vaccine would be an important step towards decreasing the disease burden caused by CHIKV infection. Despite no licensed vaccine is yet available for CHIKV, there is strong evidence of effective asymptomatic viral clearance due to neutralising antibodies against the viral structural proteins. We have designed viral-vectored vaccines to express the structural proteins of CHIKV, using the replication-deficient chimpanzee adenoviral platform, ChAdOx1. Expression of the CHIKV antigens results in the formation of chikungunya virus-like particles. Our vaccines induce high frequencies of anti-chikungunya specific T-cell responses as well as high titres of anti-CHIKV E2 antibodies with high capacity for in vitro neutralisation. Our results indicate the potential for further clinical development of the ChAdOx1 vaccine platform in CHIKV vaccinology.

Is the brazilian diverse environment is a crib for the emergence and maintenance of exotic arboviruses?

ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS

Authors: Medeiros, Daniele B. A.; Vasconcelos, Pedro Fernando C.

We review the potential of Amazon forest as a source for circulation and maintenance of native arboviruses as well its capacity to host exotic arboviruses introduced in Brazil during their process of adapting to the Amazon environment. After a brief introduction about arboviruses isolated in Amazon region and description of the main arboviruses pathogenic to humans, we highlight the history of the last two exotic viruses introduced in Brazil - Chikungunya virus (CHIKV) and Zika virus (ZIKV) - and their consequences to the public health. Finally, we discuss and hypothesize what will happen with them after the outbreak. We look to the past to predict the future.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket